AXS-05
Phase 3Small molecule
AXS-05 is one of 99 small molecule programs targeting Agitation. It is currently in Phase 3.
4
Indications
14
Total Trials
1
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Fetzima
AbbViePhase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Desvenlafaxine SR
PfizerPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
AXS-05
AAxsome Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Agitation5 trials
Major Depressive Disorder2 trials
Depression2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AXS-05. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAxsome Therapeutics, Inc.